Phosphoinositide 3‐Kinases as Potential Targets for Thrombosis Prevention

Natasha M. Setiabakti, Pia Larsson, Justin R. Hamilton

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)


As integral parts of pathological arterial thrombi, platelets are the targets of pharmacological regimens designed to treat and prevent thrombosis. A detailed understanding of platelet biology and function is thus key to design treatments that prevent thrombotic cardiovascular disease without significant disruption of the haemostatic balance. Phosphoinositide 3‐kinases (PI3Ks) are a group of lipid kinases critical to various aspects of platelet biology. There are eight PI3K isoforms, grouped into three classes. Our understanding of PI3K biology has recently progressed with the targeting of specific isoforms emerging as an attractive therapeutic strategy in various human diseases, including for thrombosis. This review will focus on the role of PI3K subtypes in platelet function and subsequent thrombus formation. Understanding the mechanisms by which platelet function is regulated by the various PI3Ks edges us closer toward targeting specific PI3K isoforms for anti‐thrombotic therapy.

Original languageEnglish
Article number4840
Number of pages14
JournalInternational Journal of Molecular Sciences
Issue number9
Publication statusPublished - 1 May 2022


  • antiplatelet therapy
  • phosphoinositide 3‐kinase
  • PI3K
  • platelets
  • thrombosis

Cite this